Hungarian techbio startup looks for partners to use and validate of its whole-cell level simulation software for testing their drug candidate and obtain valuable insights on related side effects or drug-drug interactions predicted on various cell types
A Hungarian techbio startup, specializing in cell simulation for drug discovery and using information on cellular processes, can predict protein complex changes in response to perturbations in diseases or drug treatments. The SME is looking for research partners with biotech or pharma companies involved in drug discovery to validate its platform. During a pilot study, the SME will test drug candidate(s), and provide valuable insights on related drug/side effects predicted on various cell types.